These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1263310)

  • 1. Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney.
    Morales A; Eidinger D
    J Urol; 1976 Apr; 115(4):377-80. PubMed ID: 1263310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phase II evaluation of Bacillus Calmette-Guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma.
    Laucius JF; Patel YA; Lusch CJ; Koons LS; Bellet RE; Mastrangelo MJ
    Med Pediatr Oncol; 1977; 3(3):237-42. PubMed ID: 618010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer: a phase II trial.
    Morales A; Wilson JL; Pater JL; Loeb M
    J Urol; 1982 Feb; 127(2):230-5. PubMed ID: 7038142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical review of immunotherapy of disseminated renal adenocarcinoma.
    Montie JE; Bukowski RM; James RE; Straffon RA; Stewart BH
    J Surg Oncol; 1982 Sep; 21(1):5-8. PubMed ID: 7109637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in viral warts with intradermal
    Podder I; Bhattacharya S; Mishra V; Sarkar TK; Chandra S; Sil A; Pal S; Kumar D; Saha A; Shome K; Bandyopadhyay D; Das NK
    Indian J Dermatol Venereol Leprol; 2017; 83(3):411. PubMed ID: 27852999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
    Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
    Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Instillation of bacillus Calmette-Guerin into the renal pelvis of a solitary kidney for the treatment of transitional cell carcinoma.
    Ramsey JC; Soloway MS
    J Urol; 1990 Jun; 143(6):1220-2. PubMed ID: 2342185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCG immunotherapy of metastatic adenocarcinoma of the kidney.
    Eidinger D; Morales A
    Natl Cancer Inst Monogr; 1978 Dec; (49):339-41. PubMed ID: 748790
    [No Abstract]   [Full Text] [Related]  

  • 9. Experimental percutaneous renal embolization using BCG-saturated gelfoam.
    Wright KC; Soo CS; Wallace S; McDonald MW; Ayala A
    Cardiovasc Intervent Radiol; 1982; 5(5):260-3. PubMed ID: 7159889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer.
    Guinan P; Toronchi E; Shaw M; Crispin R; Sharifi R
    Urology; 1982 Oct; 20(4):401-3. PubMed ID: 6755855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic therapies of kidney carcinoma.
    McCune CS
    Semin Oncol; 1983 Dec; 10(4):431-6. PubMed ID: 6198729
    [No Abstract]   [Full Text] [Related]  

  • 13. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder cancer immunotherapy.
    Lamm DL; Thor DE; Stogdill VD; Radwin HM
    J Urol; 1982 Nov; 128(5):931-5. PubMed ID: 6757467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
    Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin.
    Herr HW
    J Urol; 1985 Sep; 134(3):531-2. PubMed ID: 4032555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guérin immunotherapy for nonmuscle invasive bladder cancer.
    Reis LO; Ferreira U; Billis A; Cagnon VH; Fávaro WJ
    J Urol; 2012 Feb; 187(2):438-45. PubMed ID: 22177150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative intralesional Bacillus Calmette-Guérin for mammary adenocarcinoma in rats.
    Lee YT
    Cancer Res; 1977 Oct; 37(10):3679-83. PubMed ID: 908015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Crispen R; Grau D; Sarosdy MF
    J Urol; 1990 Jul; 144(1):65-7. PubMed ID: 2193172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.